

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

February 12, 2008

Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of incorporation)

000-32188
(Commission File Number)

59-3410522
(IRS Employer
Identification No.)

13700 Progress Boulevard
Alachua, Florida 32615
(Address of principal executive offices including zip code)

(386) 418-4018
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.02 Unregistered Sales of Equity Securities.

On February 12, 2008, Oragenics, Inc. (the "Company") announced that 1,150,000 warrants to purchase common stock previously issued by the Company were exercised by six warrant holders, including the Company Director David Gury, the Company Chief Scientific Officer and Director Jeffrey Hillman, and our former CEO and President, Robert Zahradnik, resulting in aggregate proceeds to the Company of \$506,000. As previously reported by the Company on Form 8-K, the private placement offering and sale of the warrants was made in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933.

A copy of the February 12, 2008 press release announcing the exercise of the warrants is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 5.02 Departure of Principal Officer; Appointment of Principal Officer

On February 12, 2008, Dr. Ronald P. Evens resigned as interim Chief Executive Officer, President so that he could devote more time to his own company and family. Dr. Evens will continue to serve as member of the Board of Directors. On February 12, 2008, the Board accepted his resignation and appointed Mr. Stanley Stein, also a member of the Board, as interim Chief Executive Officer and President. The expected tenure of his employment is until a permanent CEO is successfully recruited and retained in 2008.

There have been no changes with regards to other employees or the scientific and development team which will continue to work under Dr. Jeffrey Hillman's direction

Item 9.01 Financial Information and Exhibits.**(d) Exhibits.**

<u>Number</u>	<u>Description</u>
99.1	Press Release dated February 12, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

February 14, 2008

ORAGENICS, INC.
(Registrant)

BY: /s/ Stanley B Stein
Stanley B Stein
Interim President and Chief Executive Officer

FOR IMMEDIATE RELEASE**Oragenics Announces the Exercise of Warrants and a Management Change**

Alachua, FL (February 12, 2008) Oragenics, Inc. (AMEX:ONI) announced today that seven shareholders who received warrants as part of their March 2006 investment in Oragenics have exercised stock warrants which will provide the company with an additional \$0.5 million. The shareholders who exercised their warrants included two members of Oragenics' Board of Directors and a former Chief Executive Officer (CEO) /President. The company plans to use the proceeds of this warrant exercise to support its lead product development programs.

Dr. Jeffery Hillman, Oragenics' Chief Scientific Officer, stated "We appreciate the confidence and support expressed by our shareholders, Board members, and our former CEO/President as our company continues to progress toward achieving its strategic goals." With the exercise of these warrants, approximately 1.1 million warrants from the March 2006 private placement have been exercised.

Company Management: Dr. Ronald P. Evens, interim CEO/President and Director, notified the Board of his intention to resign as CEO/President effective February 12, 2008, so that he can devote more time to the activities of his own company and his family. Dr. Evens will continue to serve as a member of Oragenics' Board of Directors. The Board of Directors thanked Ron Evens for his valuable service to Oragenics as interim CEO.

Mr. Gury announced that Mr. Stanley B. Stein, a recently appointed director, has accepted the role of interim CEO/President until a permanent CEO can be appointed. Dr. Jeffrey Hillman, Dotti Delfino and David Gury remain the CSO, CFO and Chairman, respectively. Finally, there have been no changes with regards to other employees or to the scientific and development team which will continue to work under Dr. Hillman's direction.

About Oragenics: Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases. Our core pipeline includes products and supporting platform technologies for use in the treatment and diagnosis of bacterial infections.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact:

Oragenics, Inc.
Dotti Delfino, 386-418-4018 X232
www.oragenics.com